Saturday 17 October 2026
Export IDXX’s income statement to Excel — free account
IDEXX Laboratories, Inc.
IDXX Healthcare Diagnostics & Research
IDEXX Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 10.4% from fiscal 2024. In the quarter to June 2026, revenue grew 9.66%, EPS grew 17.2%, free cash flow grew 111.4% and total debt fell 14.3%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years, operating cash flow growth for three.
560.36
13.18
+2.41%
Follow IDXX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
36.74 | 41.01 | 51.33 | 50.27 |
+8 more quarters Free account |
P/S ratio |
9.13 | 10.07 | 12.64 | 12.28 | |
P/FCF ratio |
33.60 | 42.30 | 56.88 | 59.28 | |
P/Operating CF |
119.73 | 168.09 | 152.94 | 127.19 | |
P/B ratio |
25.78 | 28.76 | 33.89 | 32.78 | |
Price to Tangible BV |
37.67 | 43.06 | 50.31 | 49.55 | |
EV/Sales |
9.18 | 10.12 | 12.71 | 12.36 | |
EV/EBITDA |
25.93 | 28.94 | 36.33 | 35.60 | |
EV/Operating CF |
30.49 | 37.19 | 46.27 | 47.32 | |
EV/FCF |
33.80 | 42.53 | 57.16 | 59.65 | |
Quick Ratio |
0.64 | 0.62 | 0.64 | 0.62 | |
Current Ratio |
1.17 | 1.12 | 1.23 | 1.18 | |
Net Debt/EBITDA |
0.54 | 0.62 | 0.76 | 0.81 | |
Debt/Assets |
13.07% | 13.29% | 13.42% | 15.50% | |
Debt/Equity |
0.28 | 0.29 | 0.28 | 0.34 | |
Asset Turnover |
1.34 | 1.35 | 1.30 | 1.24 | |
Operating CF/Net income |
1.03 | 0.96 | 1.43 | 1.47 | |
Capex/Depreciation |
(0.65) | (0.90) | (0.77) | (1.21) | |
Interest Coverage |
41.80 | 46.84 | 34.27 | 33.30 | |
Research and Development Expense of Revenue |
5.38% | 5.77% | 6.13% | 5.74% | |
Selling, General and Administrative Expense of Revenue |
23.68% | 25.80% | 25.28% | 23.99% | |
Intangible Assets out of Total Assets |
0.15 | 0.15 | 0.16 | 0.16 | |
Share Based Compensation of Revenue |
1.32% | 1.43% | 1.48% | 1.31% | |
Graham Net Nets |
(0.01) | (0.01) | (0.01) | (0.01) | |
Graham Number |
81.15 | 77.60 | 76.94 | 74.66 | |
Earnings Yield |
2.72% | 2.44% | 1.95% | 1.99% | |
Free Cash Flow Yield |
2.98% | 2.36% | 1.76% | 1.69% | |
Revenue per Share |
15.41 | 14.32 | 13.56 | 13.80 | |
Operating CF per Share |
4.40 | 3.34 | 4.42 | 5.02 | |
Capex per Share |
(0.34) | (0.42) | (0.37) | (0.56) | |
Free Cash Flow per Share |
4.06 | 2.92 | 4.05 | 4.47 | |
Cash per Share |
2.49 | 2.52 | 2.24 | 2.60 | |
Shareholders Equity per Share |
20.42 | 19.54 | 19.96 | 19.49 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
20.42 | 19.54 | 19.96 | 19.49 | |
Free Cash Flow |
320.62 | 232.46 | 326.13 | 357.88 | |
Working Capital |
221.82 | 154.22 | 265.01 | 225.24 | |
Capital Expenditures |
(26.54) | (33.78) | (29.63) | (44.46) | |
Net Current Asset Value |
(320.27) | (375.32) | (331.55) | (348.47) | |
EV/EBIT |
28.67 | 32.01 | 40.21 | 39.42 | |
Capex to Sales |
0.02 | 0.03 | 0.03 | 0.04 | |
Price to Operating Income |
28.50 | 31.83 | 40.01 | 39.18 | |
| Other line items | |||||
Average Receivables |
593.82 | 565.50 | 512.98 | 539.07 | |
Average Payables |
122.84 | 125.04 | 112.31 | 116.43 | |
Average Inventory |
392.08 | 389.19 | 379.82 | 390.68 | |
Average Assets |
3,386.56 | 3,299.59 | 3,322.10 | 3,368.74 | |
Average Common Equity |
1,535.70 | 1,502.06 | 1,600.35 | 1,589.62 |
Columns are period end dates